Literature DB >> 6208232

Clinical spectrum of allergic and pseudoallergic drug reactions.

K P Mathews.   

Abstract

Among the many types of adverse effects of drugs, allergic reactions constitute a very significant minority, with respect to both their frequency and sometimes serious consequences. To keep the term "drug allergy" meaningful, it should be limited to those adverse drug reactions that are based on immune mechanisms or that can reasonably be presumed to have this basis. Pseudoallergic drug reactions, which will also be considered in this issue, have similar clinical manifestations and some common pathogenetic mechanisms, but the initiating event does not appear to involve a reaction between the drug or a drug metabolite and specific antibodies. Clinically, drug allergy is commonly observed in nonatopic as well as atopic people. Innumerable drugs have been reported to produce these types of reactions, but in many instances drug metabolites may be the actual culprits. Clinical manifestations of drug allergy also are legion. Unfortunately, essentially none of these is unique or specific for drug allergy, but it is important for clinicians to think of this very treatable condition along with other diagnostic possibilities. It is convenient and helpful to classify allergic reactions to drugs according to Gell and Coombs' four main types of hypersensitivity processes, but in many instances more than one mechanism may be involved, just as immune responses to most antigens generally are complex. Type I reactions are generally immunoglobulin (Ig) E-mediated, and clinical manifestations include urticaria, angioedema, respiratory symptoms, and anaphylaxis. Pseudoallergic reactions of the latter type are called anaphylactoid.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208232     DOI: 10.1016/0091-6749(84)90107-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  11 in total

Review 1.  Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis.

Authors:  J P Uetrecht
Journal:  Drug Saf       Date:  1992       Impact factor: 5.606

2.  Anticarbamazepine antibody induced by carbamazepine in a patient with severe serum sickness.

Authors:  N Hosoda; W Sunaoshi; H Shirai; Y Bando; H Miura; M Igarashi
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

Review 3.  Effect of stress on drug hypersensitivity.

Authors:  D Thomassen
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

Review 4.  Principles of pharmacotherapy: III. Drug allergy.

Authors:  T J Pallasch
Journal:  Anesth Prog       Date:  1988 Sep-Oct

Review 5.  Drug allergy: an overview.

Authors:  R D DeSwarte
Journal:  Clin Rev Allergy       Date:  1986-05

6.  The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes.

Authors:  F W Busch; A Tillmann; E W Becker; M Owsianowski; P A Berg
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Increased use of medical services and antibiotics by children who claim a prior penicillin sensitivity.

Authors:  M J Kraemer; H Caprye-Boos; H S Berman
Journal:  West J Med       Date:  1987-06

8.  An immunodominant haptenic epitope of carbamazepine detected in serum from patients given long-term treatment with carbamazepine without allergic reaction.

Authors:  M Igarashi; N Hosoda; Y Bando; K Shimanuki; W Sunaoshi; H Shirai; H Miura
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

9.  Co-trimoxazole-induced hepatic injury--an analysis of cases with hypersensitivity-like reactions.

Authors:  P A Berg; P T Daniel
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 10.  In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.